PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10570018-4	1999	On the other hand, recombinant CYP3A4 and CYP1A2 as well as CYP1A1 and CYP2D6 in microsomes from baculovirus-infected insect cells were active in azelastine N-demethylation.	azelastine	146-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37	
11948533-3	2002	Because we previously clarified that azelastine, an antiallergy and antiasthmatic drug, is N-demethylated by CYP1A2, CYP2D6, and CYP3A4 in humans, the reaction was used as a model.	azelastine	37-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135	
10570018-12	1999	Summarizing the results, azelastine N-demethylation in humans liver microsomes is catalyzed mainly by CYP3A4 and CYP2D6, and CYP1A2 to a small extent (in average, 76.6, 21.8, and 3.9%, respectively), although the percent contribution of each isoform varied among individuals.	azelastine	25-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108	
10421623-4	1999	In microsomes from baculovirus-infected insect cells, recombinant CYP3A4, 2D6, 1A2, and 2C19 exhibited high azelastine N-demethylase activity.	azelastine	108-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72	
10383922-8	1999	Azelastine and desmethylazelastine competitively inhibited CYP3A4 activity (Ki = 23.	azelastine	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65	
10383922-14	1999	The inhibition of CYP2C9, CYP2C19, and CYP3A4 activity by azelastine and its two metabolites might be clinically insignificant.	azelastine	58-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45	
9506001-1	1997	Azelastine, an antihistamine with additional pharmacologic properties, was evaluated for a possible influence on pharmacokinetic and electrocardiographic parameters due to its coadministration with CYP3A4 inhibitor ketoconazole (200 mg every 12 hrs).	azelastine	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	198-204	
9506001-8	1997	Therefore, in vitro tests and the absence of electrocardiographic effects suggests azelastine can be safely administered with CYP3A4 inhibitors.	azelastine	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132